NO319144B1 - Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren. - Google Patents

Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren. Download PDF

Info

Publication number: NO319144B1
Authority: NO; Norway
Prior art keywords: grb3; vector; sequence; grb2; protein
Prior art date: 1993-09-15

Application number

NO19960965A

Other languages

English (en)

Norwegian (no)

Other versions

NO960965D0 (no

NO960965L (no

Inventor

Fabien Schweighoffer

Bruno Tocque

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-15

Filing date

1996-03-08

Publication date

2005-06-27

1996-03-08 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

1996-03-08 Publication of NO960965D0 publication Critical patent/NO960965D0/no

1996-03-08 Publication of NO960965L publication Critical patent/NO960965L/no

2005-06-27 Publication of NO319144B1 publication Critical patent/NO319144B1/no

Links

239000013598 vector Substances 0.000 title claims abstract description 27
239000002773 nucleotide Substances 0.000 title claims abstract description 11
125000003729 nucleotide group Chemical group 0.000 title claims abstract description 11
239000008194 pharmaceutical composition Substances 0.000 title 1
101150098203 grb2 gene Proteins 0.000 claims description 37
101100015729 Drosophila melanogaster drk gene Proteins 0.000 claims description 33
241000700605 Viruses Species 0.000 claims description 16
206010028980 Neoplasm Diseases 0.000 claims description 14
230000014509 gene expression Effects 0.000 claims description 11
239000000825 pharmaceutical preparation Substances 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 9
241000701161 unidentified adenovirus Species 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
241001430294 unidentified retrovirus Species 0.000 claims description 6
229920002307 Dextran Polymers 0.000 claims description 3
102000007999 Nuclear Proteins Human genes 0.000 claims description 3
108010089610 Nuclear Proteins Proteins 0.000 claims description 3
108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
150000002632 lipids Chemical class 0.000 claims description 3
239000002502 liposome Substances 0.000 claims description 3
239000013603 viral vector Substances 0.000 claims description 3
241000702421 Dependoparvovirus Species 0.000 claims description 2
229960005486 vaccine Drugs 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 46
102000004169 proteins and genes Human genes 0.000 abstract description 29
238000000034 method Methods 0.000 abstract description 18
230000030833 cell death Effects 0.000 abstract description 8
230000001939 inductive effect Effects 0.000 abstract description 3
230000000692 anti-sense effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 36
235000018102 proteins Nutrition 0.000 description 27
230000000694 effects Effects 0.000 description 16
108020004414 DNA Proteins 0.000 description 12
102000005720 Glutathione transferase Human genes 0.000 description 11
108010070675 Glutathione transferase Proteins 0.000 description 11
108091034117 Oligonucleotide Proteins 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
230000002950 deficient Effects 0.000 description 10
239000012634 fragment Substances 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
239000013612 plasmid Substances 0.000 description 8
239000000047 product Substances 0.000 description 8
230000027455 binding Effects 0.000 description 7
108020004999 messenger RNA Proteins 0.000 description 7
150000007523 nucleic acids Chemical class 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
230000006907 apoptotic process Effects 0.000 description 6
108020001507 fusion proteins Proteins 0.000 description 6
102000037865 fusion proteins Human genes 0.000 description 6
102000016914 ras Proteins Human genes 0.000 description 6
108010014186 ras Proteins Proteins 0.000 description 6
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000037430 deletion Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
230000003993 interaction Effects 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
230000007170 pathology Effects 0.000 description 5
108700042226 ras Genes Proteins 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
108020004705 Codon Proteins 0.000 description 4
102000001301 EGF receptor Human genes 0.000 description 4
108060006698 EGF receptor Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000012546 transfer Methods 0.000 description 4
241000701022 Cytomegalovirus Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 3
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
235000002374 tyrosine Nutrition 0.000 description 3
OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 2
LAGUSEHJTGJJRJ-UHFFFAOYSA-N 2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)-2-oxoethyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(C(=O)CNC(=O)C(CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC LAGUSEHJTGJJRJ-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000701533 Escherichia virus T4 Species 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
241001135569 Human adenovirus 5 Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
101710088675 Proline-rich peptide Proteins 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
231100000590 oncogenic Toxicity 0.000 description 2
230000002246 oncogenic effect Effects 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
101100217475 Arabidopsis thaliana ACA1 gene Proteins 0.000 description 1
101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
101150040459 RAS gene Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241001068295 Replication defective viruses Species 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
108700022176 SOS1 Proteins 0.000 description 1
102000057028 SOS1 Human genes 0.000 description 1
101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 1
101100533932 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SPA2 gene Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108010059447 Son of Sevenless Proteins Proteins 0.000 description 1
102000005588 Son of Sevenless Proteins Human genes 0.000 description 1
101150100839 Sos1 gene Proteins 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
230000035800 maturation Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
230000006740 morphological transformation Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000131 polyvinylidene Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000001173 tumoral effect Effects 0.000 description 1
230000007306 turnover Effects 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
238000012795 verification Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)

NO19960965A 1993-09-15 1996-03-08 Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren. NO319144B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9310971A FR2710074B1 (fr)	1993-09-15	1993-09-15	Gène GRB3-3, ses variants et leurs utilisations.
PCT/FR1994/000542 WO1995007981A1 (fr)	1993-09-15	1994-05-09	Gene grb3-3, ses variants et leurs utilisations

Publications (3)

Publication Number	Publication Date
NO960965D0 NO960965D0 (no)	1996-03-08
NO960965L NO960965L (no)	1996-03-08
NO319144B1 true NO319144B1 (no)	2005-06-27

Family

ID=9450882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19960965A NO319144B1 (no)	1993-09-15	1996-03-08	Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren.

Country Status (27)

Country	Link
US (2)	US5831048A (fi)
EP (1)	EP0719328B1 (fi)
JP (1)	JP3794697B2 (fi)
KR (1)	KR100330477B1 (fi)
CN (1)	CN1098930C (fi)
AT (1)	ATE196926T1 (fi)
AU (1)	AU698819B2 (fi)
BR (1)	BR9407693A (fi)
CA (1)	CA2169938A1 (fi)
CZ (1)	CZ288882B6 (fi)
DE (1)	DE69426121T2 (fi)
DK (1)	DK0719328T3 (fi)
ES (1)	ES2152313T3 (fi)
FI (1)	FI120499B (fi)
FR (1)	FR2710074B1 (fi)
GR (1)	GR3034600T3 (fi)
HU (1)	HU221516B (fi)
IL (2)	IL126756A (fi)
NO (1)	NO319144B1 (fi)
NZ (1)	NZ266162A (fi)
PL (1)	PL178402B1 (fi)
PT (1)	PT719328E (fi)
RU (1)	RU2159815C2 (fi)
SK (1)	SK281123B6 (fi)
UA (1)	UA46715C2 (fi)
WO (1)	WO1995007981A1 (fi)
ZA (1)	ZA947059B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2732348B1 (fr) *	1995-03-31	1997-04-30	Rhone Poulenc Rorer Sa	Systeme d'expression conditionnel
US6171800B1 (en)	1995-06-07	2001-01-09	Biogen, Inc.	Method of making and binding CAIP polypeptides
US5837844A (en) *	1995-06-07	1998-11-17	Biogen, Inc.	CAIP-like gene family
US6423824B1 (en)	1995-06-07	2002-07-23	Biogen, Inc.	CAIP-like gene family
US5855911A (en) *	1995-08-29	1999-01-05	Board Of Regents, The University Of Texas System	Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
AU6342696A (en) *	1996-06-27	1998-01-14	Biogen, Inc.	The caip-like gene family
US7309692B1 (en)	1996-07-08	2007-12-18	Board Of Regents, The University Of Texas System	Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) *	1996-10-04	2005-12-20	Board Of Regents, The University Of Texas Systems	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7285288B1 (en)	1997-10-03	2007-10-23	Board Of Regents, The University Of Texas System	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en)	1997-10-03	2010-04-27	Board Of Regents, The University Of Texas System	Small oligonucleotides with anti-tumor activity
EP0998945A1 (en) *	1998-09-30	2000-05-10	Transgene S.A.	Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
IL151928A0 (en)	2000-03-30	2003-04-10	Whitehead Biomedical Inst	Rna sequence-specific mediators of rna interference
RU2322500C2 (ru)	2000-12-01	2008-04-20	Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф.	Малые молекулы рнк, опосредующие интерференцию рнк
US20040043950A1 (en) *	2002-01-03	2004-03-04	Board Of Regents, The University Of Texas System	WT1 antisense oligos for the inhibition of breast cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE187772T1 (de)	1991-01-18	2000-01-15	Univ New York	Cdns-klonierungsverfahren für rezeptortyrosinkinasezielprotein und hgrb- proteine
AU5136093A (en) *	1992-09-25	1994-04-26	Warner-Lambert Company	Peptide antagonists of sh2 binding and therapeutic uses thereof

1993
- 1993-09-15 FR FR9310971A patent/FR2710074B1/fr not_active Expired - Fee Related
1994
- 1994-05-09 BR BR9407693A patent/BR9407693A/pt not_active Application Discontinuation
- 1994-05-09 DK DK94915598T patent/DK0719328T3/da active
- 1994-05-09 EP EP94915598A patent/EP0719328B1/fr not_active Expired - Lifetime
- 1994-05-09 JP JP50901595A patent/JP3794697B2/ja not_active Expired - Fee Related
- 1994-05-09 AT AT94915598T patent/ATE196926T1/de not_active IP Right Cessation
- 1994-05-09 CN CN94193814A patent/CN1098930C/zh not_active Expired - Fee Related
- 1994-05-09 UA UA96030994A patent/UA46715C2/uk unknown
- 1994-05-09 SK SK345-96A patent/SK281123B6/sk not_active IP Right Cessation
- 1994-05-09 RU RU96107888/13A patent/RU2159815C2/ru active
- 1994-05-09 CZ CZ1996758A patent/CZ288882B6/cs not_active IP Right Cessation
- 1994-05-09 ES ES94915598T patent/ES2152313T3/es not_active Expired - Lifetime
- 1994-05-09 US US08/612,857 patent/US5831048A/en not_active Ceased
- 1994-05-09 PT PT94915598T patent/PT719328E/pt unknown
- 1994-05-09 KR KR1019960701323A patent/KR100330477B1/ko not_active IP Right Cessation
- 1994-05-09 US US09/641,640 patent/USRE37952E1/en not_active Expired - Fee Related
- 1994-05-09 DE DE69426121T patent/DE69426121T2/de not_active Expired - Fee Related
- 1994-05-09 NZ NZ266162A patent/NZ266162A/en not_active IP Right Cessation
- 1994-05-09 PL PL94313445A patent/PL178402B1/pl not_active IP Right Cessation
- 1994-05-09 CA CA002169938A patent/CA2169938A1/fr not_active Abandoned
- 1994-05-09 AU AU67247/94A patent/AU698819B2/en not_active Ceased
- 1994-05-09 WO PCT/FR1994/000542 patent/WO1995007981A1/fr active IP Right Grant
- 1994-05-09 HU HU9600668A patent/HU221516B/hu not_active IP Right Cessation
- 1994-09-12 IL IL126756A patent/IL126756A/en not_active IP Right Cessation
- 1994-09-12 IL IL11094294A patent/IL110942A/en not_active IP Right Cessation
- 1994-09-13 ZA ZA947059A patent/ZA947059B/xx unknown
1996
- 1996-03-08 NO NO19960965A patent/NO319144B1/no not_active IP Right Cessation
- 1996-03-14 FI FI961202A patent/FI120499B/fi active IP Right Grant
2000
- 2000-10-12 GR GR20000401514T patent/GR3034600T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
PL313445A1 (en)	1996-07-08
DE69426121D1 (de)	2000-11-16
NO960965D0 (no)	1996-03-08
HU9600668D0 (en)	1996-05-28
CZ75896A3 (en)	1996-06-12
AU698819B2 (en)	1998-11-05
CZ288882B6 (cs)	2001-09-12
FI120499B (fi)	2009-11-13
PL178402B1 (pl)	2000-04-28
HUT74273A (en)	1996-11-28
GR3034600T3 (en)	2001-01-31
IL110942A (en)	2001-12-23
AU6724794A (en)	1995-04-03
ATE196926T1 (de)	2000-10-15
IL110942A0 (en)	1994-11-28
HU221516B (hu)	2002-11-28
KR100330477B1 (ko)	2002-12-02
RU2159815C2 (ru)	2000-11-27
CN1098930C (zh)	2003-01-15
IL126756A (en)	2006-06-11
EP0719328B1 (fr)	2000-10-11
ZA947059B (en)	1995-05-18
ES2152313T3 (es)	2001-02-01
DK0719328T3 (da)	2000-11-13
US5831048A (en)	1998-11-03
JP3794697B2 (ja)	2006-07-05
PT719328E (pt)	2001-02-28
BR9407693A (pt)	1997-02-04
EP0719328A1 (fr)	1996-07-03
NO960965L (no)	1996-03-08
NZ266162A (en)	1997-11-24
JPH09502357A (ja)	1997-03-11
WO1995007981A1 (fr)	1995-03-23
FR2710074A1 (fr)	1995-03-24
FI961202A (fi)	1996-03-14
CA2169938A1 (fr)	1995-03-23
FR2710074B1 (fr)	1995-12-08
CN1133064A (zh)	1996-10-09
DE69426121T2 (de)	2001-05-31
USRE37952E1 (en)	2002-12-31
SK281123B6 (sk)	2000-12-11
UA46715C2 (uk)	2002-06-17
FI961202A0 (fi)	1996-03-14
SK34596A3 (en)	1996-07-03

Legal Events

Date	Code	Title	Description
2010-12-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO319144B1 (no)	2005-06-27	Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren.
CA2197890A1 (en)	1996-02-29	Retinoblastoma protein-interacting zinc finger proteins
WO2002019965A2 (en)	2002-03-14	Heat shock response and virus replication
WO2015001045A2 (en)	2015-01-08	Pro-apoptotic ras and raf peptides
US6323335B1 (en)	2001-11-27	Retinoblastoma protein-interacting zinc finger proteins
NO321455B1 (no)	2006-05-15	Anvendelse av en forbindelse som inhiberer bindingen av faktor AP1 til sekvens SEQ ID Nr. 1 til fremstilling av et medikament til behandling av og/eller forebygging av neurodegenerative lidelser.
AU722973B2 (en)	2000-08-17	Grb3-3 gene, variants and uses thereof
CN117756909A (zh)	2024-03-26	改进的抗衰老化合物及其在癌症治疗中的用途
WO2016156538A1 (en)	2016-10-06	Peptides that inhibit binding between set and caspase-9
US20030083482A1 (en)	2003-05-01	Compositions and methods for p53-mediated repression of gene expression
KR102566745B1 (ko)	2023-08-18	암의 예방 또는 치료를 위한 Runx3 변이 단백질
Xu et al.	2000	Molecular cloning and characterization of FX3, a novel zinc-finger protein.
US20030105008A1 (en)	2003-06-05	Geminin and Orc3N inhibit replication of herpesviruses, papillomaviruses, and polyomaviruses
KR101826249B1 (ko)	2018-02-06	융합 단백질 및 이를 포함하는 세포주기 조절제
EP4313110A1 (en)	2024-02-07	K-ras inhibitor
US20100317598A1 (en)	2010-12-16	Isolated BRCA1 Peptides and Method of Use
US20060160732A1 (en)	2006-07-20	Compositions and methods for inhibiting cell senescence and hyperproliferative disorders
JP2002516096A (ja)	2002-06-04	転写調節に使用するための、ＣＲＥＢ結合タンパク質および関連するｐ３００由来のポリペプチド
NO315895B1 (no)	2003-11-10	Farmasöytisk preparat for kontroll av cellesyklusutvikling, fremstilling avdette for regulering av cellesyklusutvikling i en celle sommangler et funksjonelt retinoblastomtumorsuppressorprotein, samt fremgangsmåte forkontroll av cellesyklusutv